Key Takeaways: The FAPI PET scan (68Ga FAPI PET/CT) targets fibroblast activation protein in the tumour microenvironment, enabling highly sensitive cancer detection in tumour types where FDG PET/CT consistently underperforms — including pancreatic, gastric, colorectal, hepatic, and biliary cancers. It also enables pre-treatment mapping for FAP-targeted radionuclide therapy. Neurad Diagnostics provides daily 68Ga FAPI PET/CT via its in-house Gallium Generator, making this advanced investigation routinely accessible to oncologists and patients.
FAPI PET Scan: A New Era in Tumour Microenvironment Imaging
The FAPI PET scan (68Ga-FAPI PET/CT — Fibroblast Activation Protein Inhibitor Positron Emission Tomography / Computed Tomography) represents one of the most significant recent advances in oncological imaging. Its development addresses a fundamental limitation of conventional FDG PET/CT: the dependence on tumour cell glucose metabolism as the imaging target. While FDG is an excellent agent for highly glycolytic tumours such as lymphoma, lung cancer, and melanoma, a large and clinically important group of solid tumours displays low or variable FDG avidity — rendering conventional PET/CT unreliable for staging these cancers. The FAPI PET scan solves this problem by targeting a completely different biological substrate: fibroblast activation protein (FAP), a serine protease selectively expressed on cancer-associated fibroblasts (CAFs) within the tumour stroma.
Cancer-associated fibroblasts are abundant in the reactive stroma of most solid tumours — typically comprising 40–90% of the total tumour cell mass in pancreatic, gastric, and colorectal cancers. Their high FAP expression, combined with negligible FAP expression in normal adult tissues, creates an ideal imaging target with high tumour-to-background contrast. When 68Ga-FAPI is injected intravenously, it binds to FAP-expressing CAFs throughout the body, producing PET images with exceptionally low background noise and high lesion conspicuity. The result is a scan that can detect tumour deposits that are simply invisible on FDG PET/CT.
Neurad Diagnostics has incorporated 68Ga FAPI PET/CT into its clinical imaging portfolio through our in-house 68Ga Gallium Generator, making this advanced imaging modality available daily without the supply-chain limitations that restrict FAPI availability at most centres. Our nuclear medicine reporting team has dedicated expertise in FAPI scan interpretation across all relevant tumour types.
How the FAPI PET Scan Works: The Tumour Stroma as a Target
Understanding why the FAPI PET scan represents a paradigm shift requires a basic appreciation of tumour biology. When cancer cells proliferate and invade surrounding tissue, they do not exist in isolation — they recruit and activate normal fibroblasts in the surrounding stroma to form cancer-associated fibroblasts. These CAFs produce growth factors, extracellular matrix components, and proteases that support tumour invasion, angiogenesis, and immune evasion. One of the signature molecular markers of CAF activation is the enzyme fibroblast activation protein alpha (FAPα), which is expressed at very low levels in normal adult tissue but massively upregulated in CAFs.
The 68Ga-FAPI radiopharmaceutical is a small molecule inhibitor of FAPα that has been conjugated to a DOTA chelator for radiolabelling with gallium-68. After intravenous injection, it rapidly distributes through the bloodstream, binds to FAPα-expressing CAFs in tumours throughout the body, and — crucially — clears quickly from normal tissues. This kinetic profile produces images with very high tumour-to-background contrast as early as 30–60 minutes post-injection. Unlike FDG, which accumulates in the brain and myocardium (creating background noise that can mask head and thoracic lesions), FAPI shows minimal uptake in these tissues, offering a cleaner imaging backdrop.
FAPI PET Scan Indications: Which Cancers Benefit Most?
Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the most FAP-rich tumours in oncology, with CAFs comprising up to 90% of tumour volume in some pathological specimens. FAPI PET scan demonstrates dramatically higher tumour-to-background contrast for pancreatic cancer than FDG PET/CT, which is frequently limited by the physiologically high FDG activity of the adjacent duodenum and the desmoplastic, low-metabolic-activity stroma of PDAC. Multiple published series confirm that FAPI PET/CT detects more local extension, more lymph node metastases, and more peritoneal implants in PDAC than FDG — with direct implications for resectability assessment and treatment planning.
Gastric Cancer
Gastric cancer, particularly the diffuse (signet ring cell) subtype, is well-known as a poorly FDG-avid tumour. FAPI PET scan consistently demonstrates superior detection of gastric cancer primary lesions and peritoneal metastases compared to FDG PET/CT. Accurate pre-treatment staging of peritoneal disease is of critical importance in gastric cancer, as peritoneal carcinomatosis precludes curative resection and directly determines treatment strategy. FAPI PET/CT at Neurad Diagnostics provides this crucial pre-operative information with a level of accuracy not achievable with FDG imaging.
Colorectal Cancer with Peritoneal Metastases
Peritoneal carcinomatosis from colorectal cancer is a particularly challenging imaging scenario, as peritoneal implants are frequently small (sub-centimetre), flat, and poorly FDG-avid — making them invisible on conventional FDG PET/CT and difficult to characterise on CT alone. FAPI PET scan demonstrates substantially improved detection of peritoneal disease in colorectal cancer, with implications for the selection of patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Accurate pre-operative FAPI staging can prevent futile surgical interventions in patients with unresectable peritoneal disease extent.
Hepatocellular Carcinoma and Cholangiocarcinoma
FDG PET/CT has limited sensitivity for well-differentiated HCC and cholangiocarcinoma due to the high physiological FDG background in the liver parenchyma. FAPI PET scan demonstrates superior lesion detection in both tumour types, with particularly impressive performance for intrahepatic cholangiocarcinoma — a tumour type with very high FAP expression in its characteristic desmoplastic stroma. FAPI PET/CT is increasingly used for staging, surgical planning, and treatment response assessment in hepatobiliary oncology at centres with access to this technology.
Breast Cancer Staging and Restaging
Lobular breast carcinoma and some low-grade ductal carcinomas are characteristically FDG-negative, creating staging challenges with conventional PET/CT. FAPI PET scan demonstrates high sensitivity for lobular breast carcinoma, invasive ductal carcinoma with extensive stromal reaction, and bone metastases in breast cancer — the last being a particularly important advantage, as bone metastases from breast cancer can be predominantly sclerotic and FDG-negative. FAPI also demonstrates superior detection of soft tissue metastases and pericardial/pleural involvement, expanding its role in the advanced breast cancer setting.
Head and Neck Cancers
In head and neck squamous cell carcinomas (HNSCC) and thyroid cancers, FAPI PET scan offers high tumour-to-background contrast with minimal uptake in the brain and salivary glands — areas where FDG background can be problematic. It is particularly useful for recurrent or residual HNSCC after chemoradiotherapy, where treatment-induced FDG uptake in inflamed tissue creates diagnostic ambiguity that FAPI largely avoids.
Bone and Soft Tissue Metastases
FAPI PET scan demonstrates excellent sensitivity for bone metastases across multiple cancer types — including purely lytic lesions that can be missed by bone scan and poorly FDG-avid sclerotic lesions. For soft tissue metastases, FAPI frequently provides superior lesion-to-background contrast compared to FDG, facilitating more accurate disease burden assessment for systemic therapy decisions. [Insert External Link to FAPI clinical review EJNMMI, NCBI PubMed]
FAPI PET/CT for Radiotherapy Planning: Tumour Volume Delineation
An important and growing application of FAPI PET scan is in the delineation of gross tumour volume (GTV) for radiation therapy planning. For tumours where CT or MRI provides equivocal tumour boundaries, or where tumour-to-normal tissue contrast on anatomical imaging is poor, FAPI PET/CT can provide significantly improved tumour boundary definition. This is particularly relevant in pancreatic cancer radiotherapy, rectal cancer treatment planning, and post-treatment assessment of head and neck cancer.
FAPI PET data can be co-registered with dedicated radiotherapy planning CT datasets to incorporate molecular tumour volume information directly into treatment planning systems. Neurad Diagnostics provides image export formats compatible with all major radiotherapy planning platforms, and our nuclear medicine physicians can consult directly with radiation oncologists on FAPI-based GTV contouring protocols.
FAPI PET Scan for Theranostics: From Diagnosis to Targeted Therapy
The FAPI PET scan is the diagnostic partner to an emerging class of FAP-targeted radionuclide therapies. Just as PSMA PET/CT identifies prostate cancer patients for 177Lu-PSMA therapy, FAPI PET/CT identifies patients with high FAP expression suitable for 177Lu-FAPI or 90Y-FAPI treatment — delivering high-dose targeted radiation directly to cancer-associated fibroblasts throughout the body. While FAP-targeted therapy is currently available primarily through clinical trials, the data emerging from early-phase studies is encouraging, particularly for cancers with limited conventional treatment options.
Neurad Diagnostics provides FAPI PET/CT with specific theranostic-intent reporting for patients being evaluated for FAP-targeted therapies, including quantitative FAP expression assessment (SUVmax, tumour-to-liver ratio) and whole-body disease burden metrics that are required by therapy planning protocols. [Insert Internal Link to Theranostics Programme Page]
FAPI PET Scan Preparation and Procedure
Preparation for FAPI PET scan at Neurad Diagnostics is straightforward and represents one of the practical advantages of this modality over FDG PET/CT: fasting is not required, and blood glucose management — a significant logistical challenge in diabetic patients undergoing FDG scanning — is not necessary for FAPI. The following preparation guidelines apply.
FAPI PET Scan Preparation Guidelines
- Fasting: Fasting is not strictly required for FAPI PET/CT in most protocols. Our team may recommend a 2-hour fast from food for comfort during the procedure, but extensive fasting is not necessary.
- Diabetic patients: No specific blood glucose management is required — a major advantage over FDG PET/CT.
- Medications: Continue all regular medications. No special medication holds are required.
- Hydration: Drink 500 mL of water before arrival to promote renal clearance of unbound tracer.
- Duration: Allow 1.5–2 hours total. FAPI allows earlier scanning (30–60 minutes post-injection) compared to FDG (60–90 minutes), making it a shorter appointment overall.
- Clothing: Loose, comfortable clothing without metal. Remove jewellery.
FAPI PET Scan vs. FDG PET/CT: A Direct Comparison
Both FAPI and FDG PET/CT are valid oncological imaging agents that target fundamentally different biological processes. The choice between them — or the decision to use both — depends on the specific tumour type and clinical question. The key advantages of FAPI PET scan over FDG are: superior tumour detection in FDG-negative or low-FDG-avid tumours; lower background signal in the brain, liver, and myocardium enabling more sensitive detection of metastases in these locations; no fasting or glucose management requirement; faster image acquisition; and the ability to image tumour stroma rather than tumour cells — a distinct biological compartment that FDG is blind to.
FDG remains superior for: aggressive lymphoma, lung cancer (especially adenocarcinoma and squamous cell), melanoma, and high-grade carcinomas where tumour cell glycolysis is the dominant imaging substrate. In many complex oncological scenarios — particularly the initial staging of potentially resectable pancreatic cancer, gastric cancer, or peritoneal malignancy — performing both FDG and FAPI PET/CT provides the most complete staging information and can be co-ordinated at Neurad Diagnostics on the same or consecutive days.
Frequently Asked Questions: FAPI PET Scan
What cancers are best imaged with FAPI PET scan?
FAPI PET scan delivers its greatest advantage over FDG in pancreatic cancer, gastric cancer, colorectal cancer with peritoneal disease, hepatocellular carcinoma, cholangiocarcinoma, lobular breast carcinoma, and sarcomas. It also performs well in lung cancer, head and neck cancer, ovarian cancer, and cervical cancer. The general principle is that tumours with a prominent desmoplastic stroma and abundant cancer-associated fibroblasts will show high FAPI uptake.
Is FAPI PET scan better than FDG PET/CT?
FAPI PET scan is not universally “better” than FDG — it is complementary and superior in specific clinical contexts. For FDG-avid lymphomas and aggressive carcinomas, FDG remains the first-line choice. For tumour types with low FDG avidity and high FAP expression — particularly gastrointestinal, hepatobiliary, and desmoplastic tumours — FAPI consistently outperforms FDG. Your nuclear medicine consultant at Neurad Diagnostics can advise on the optimal imaging strategy for each individual case.
How is FAPI PET scan reported?
FAPI PET/CT reports at Neurad Diagnostics follow systematic anatomical reporting standards with lesion-level documentation of FAP expression (SUVmax), size (on low-dose CT), and anatomical site. A summary staging assessment and comparison to prior imaging is provided where available. For theranostic-intent scans, quantitative tumour burden metrics are included. Reports are available within 24 hours of the scan in most cases.
Why Neurad Diagnostics Is the Specialist Centre for FAPI PET/CT
FAPI PET scan is at the cutting edge of clinical nuclear medicine, available at only a handful of centres in India. The requirement for an in-house 68Ga Gallium Generator is the primary technical barrier that limits its availability — and Neurad Diagnostics has met this requirement through significant investment in our radiopharmaceutical production infrastructure. Our daily FAPI PET/CT service means that patients with urgent staging requirements — particularly those with potentially resectable pancreatic or gastric cancer where rapid pre-operative staging is critical — can receive this investigation promptly, without waiting weeks for an appointment at a facility dependent on external tracer supply.
Our nuclear medicine physicians have developed clinical expertise in FAPI interpretation across the full spectrum of indications described above, and are available for direct referrer consultation on complex cases. If your patient has a tumour that has been challenging to stage with FDG PET/CT or conventional imaging, FAPI PET/CT at Neurad Diagnostics may be the answer. Contact us to discuss. [Insert Internal Link to Contact Page] [Insert Internal Link to FAPI Scan Appointment Page]